- Home
- GLPG vs PLUS Comparison
GLPG vs PLUS Comparison
Compare GLPG & PLUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- PLUS
- Stock Information
- Founded
- GLPG 1999
- PLUS 1990
- Country
- GLPG Belgium
- PLUS United States
- Employees
- GLPG N/A
- PLUS N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- PLUS Retail: Computer Software & Peripheral Equipment
- Sector
- GLPG Health Care
- PLUS Technology
- Exchange
- GLPG Nasdaq
- PLUS Nasdaq
- Market Cap
- GLPG 2.1B
- PLUS 2.0B
- IPO Year
- GLPG 2005
- PLUS 1996
- Fundamental
- Price
- GLPG $30.42
- PLUS $88.78
- Analyst Decision
- GLPG Hold
- PLUS
- Analyst Count
- GLPG 4
- PLUS 0
- Target Price
- GLPG $31.33
- PLUS N/A
- AVG Volume (30 Days)
- GLPG 169.3K
- PLUS 178.3K
- Earning Date
- GLPG 11-05-2025
- PLUS 11-06-2025
- Dividend Yield
- GLPG N/A
- PLUS 1.11%
- EPS Growth
- GLPG N/A
- PLUS 14.25
- EPS
- GLPG N/A
- PLUS 4.60
- Revenue
- GLPG $336,643,201.00
- PLUS $2,285,906,000.00
- Revenue This Year
- GLPG $1.77
- PLUS $7.12
- Revenue Next Year
- GLPG $0.44
- PLUS N/A
- P/E Ratio
- GLPG N/A
- PLUS $19.52
- Revenue Growth
- GLPG 10.31
- PLUS 9.24
- 52 Week Low
- GLPG $22.36
- PLUS $53.83
- 52 Week High
- GLPG $37.78
- PLUS $92.66
- Technical
- Relative Strength Index (RSI)
- GLPG 41.14
- PLUS 71.29
- Support Level
- GLPG $30.17
- PLUS $86.81
- Resistance Level
- GLPG $33.12
- PLUS $91.37
- Average True Range (ATR)
- GLPG 0.75
- PLUS 3.18
- MACD
- GLPG -0.04
- PLUS 0.97
- Stochastic Oscillator
- GLPG 22.55
- PLUS 85.78
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About PLUS ePlus inc.
ePlus Inc is a provider of technology solutions across the IT spectrum, spanning security, cloud, data center, networking, collaboration, AI, service provider, and critical infrastructure, and emerging solutions, to domestic and foreign organizations across all industry segments. Its solutions leverage a broad range of professional, consultative, and managed services across the technology spectrum. The company possesses top-level engineering certifications with a broad range of IT technologies that enable the company to offer multi-vendor IT solutions that are optimized for each of its customers' specific requirements. It also offers a wide portfolio of technology and other capital asset financing solutions to customers across commercial and government enterprises, designing programs.